PL3157549T3 - Nowa immunoterapia przeciwko szeregu nowotworom krwi, w szczególności przeciwko przewlekłej białaczce limfatycznej (CLL) - Google Patents

Nowa immunoterapia przeciwko szeregu nowotworom krwi, w szczególności przeciwko przewlekłej białaczce limfatycznej (CLL)

Info

Publication number
PL3157549T3
PL3157549T3 PL15730135T PL15730135T PL3157549T3 PL 3157549 T3 PL3157549 T3 PL 3157549T3 PL 15730135 T PL15730135 T PL 15730135T PL 15730135 T PL15730135 T PL 15730135T PL 3157549 T3 PL3157549 T3 PL 3157549T3
Authority
PL
Poland
Prior art keywords
cll
blood
lymphoid leukemia
against several
chronic lymphoid
Prior art date
Application number
PL15730135T
Other languages
English (en)
Polish (pl)
Inventor
Juliane STICKEL
Daniel Kowalewski
Hans-Georg Rammensee
Stefan Stevanovic
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PL3157549T3 publication Critical patent/PL3157549T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL15730135T 2014-06-20 2015-06-17 Nowa immunoterapia przeciwko szeregu nowotworom krwi, w szczególności przeciwko przewlekłej białaczce limfatycznej (CLL) PL3157549T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462014849P 2014-06-20 2014-06-20
GBGB1411037.3A GB201411037D0 (en) 2014-06-20 2014-06-20 Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
EP15730135.9A EP3157549B1 (en) 2014-06-20 2015-06-17 Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
PCT/EP2015/063566 WO2015193359A2 (en) 2014-06-20 2015-06-17 Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)

Publications (1)

Publication Number Publication Date
PL3157549T3 true PL3157549T3 (pl) 2020-12-14

Family

ID=51409910

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15730135T PL3157549T3 (pl) 2014-06-20 2015-06-17 Nowa immunoterapia przeciwko szeregu nowotworom krwi, w szczególności przeciwko przewlekłej białaczce limfatycznej (CLL)

Country Status (14)

Country Link
EP (2) EP3157549B1 (OSRAM)
JP (1) JP6560261B2 (OSRAM)
CA (1) CA2950827A1 (OSRAM)
DK (1) DK3157549T3 (OSRAM)
ES (1) ES2802155T3 (OSRAM)
GB (1) GB201411037D0 (OSRAM)
HU (1) HUE050070T2 (OSRAM)
LT (1) LT3157549T (OSRAM)
PL (1) PL3157549T3 (OSRAM)
PT (1) PT3157549T (OSRAM)
RS (1) RS60592B1 (OSRAM)
SI (1) SI3157549T1 (OSRAM)
TW (3) TW201930347A (OSRAM)
WO (1) WO2015193359A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
KR20180100302A (ko) 2015-10-23 2018-09-10 우니베르지태트 트벤테 인테그린 결합 펩티드 및 그의 용도
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
CN114028549A (zh) 2016-02-19 2022-02-11 伊玛提克斯生物技术有限公司 用于nhl和其他癌症免疫治疗的新型肽和肽组合物
IL302705A (en) 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combination of peptides, and cell-based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
CR20200608A (es) 2016-04-21 2021-01-20 Immatics Biotechnologies Gmbh INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551)
EA201892333A1 (ru) * 2016-04-21 2019-03-29 Имматикс Байотекнолоджиз Гмбх Иммунотерапия меланомы и других видов рака
DE102016005550B4 (de) 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvans zur lnduzierung einer zellulären lmmunantwort
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
CN107602682A (zh) * 2016-07-07 2018-01-19 胡国田 一种多肽及其应用
TWI796299B (zh) 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR20190137858A (ko) 2017-04-10 2019-12-11 이매틱스 바이오테크놀로지스 게엠베하 백혈병 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
WO2018189152A2 (en) * 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
EP3827022A1 (en) * 2018-08-11 2021-06-02 Baerlecken, Niklas Autoantibodies binding to negative elongation factor e (nelf-e) for diagnosing sarcoidosis
CN109593125A (zh) * 2018-12-12 2019-04-09 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p1及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
WO1994029347A1 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
WO1997026328A1 (en) 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP2004503213A (ja) 2000-03-27 2004-02-05 テクニオン　リサーチ　アンド　ディベロップメント　ファウンデーション　リミテッド １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU2001275246B2 (en) 2000-06-05 2006-06-29 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use thereof
US20040053292A1 (en) * 2000-11-15 2004-03-18 Jurg Tschopp Proteins and dna sequences underlying these proteins used for treating inflammations
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
NZ539226A (en) 2002-11-09 2008-09-26 Medigene Ltd T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
DE602005013670D1 (de) * 2004-05-21 2009-05-14 Inst Systems Biology Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
CA2816225A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors

Also Published As

Publication number Publication date
DK3157549T3 (da) 2020-06-22
ES2802155T3 (es) 2021-01-15
EP3157549A2 (en) 2017-04-26
SI3157549T1 (sl) 2020-08-31
TW202024125A (zh) 2020-07-01
EP3708185A3 (en) 2020-11-04
JP6560261B2 (ja) 2019-08-14
RS60592B1 (sr) 2020-08-31
JP2017525336A (ja) 2017-09-07
WO2015193359A3 (en) 2016-02-25
GB201411037D0 (en) 2014-08-06
EP3708185A2 (en) 2020-09-16
CA2950827A1 (en) 2015-12-23
LT3157549T (lt) 2020-08-10
HUE050070T2 (hu) 2020-11-30
TW201930347A (zh) 2019-08-01
TWI670282B (zh) 2019-09-01
WO2015193359A2 (en) 2015-12-23
TW201613956A (en) 2016-04-16
PT3157549T (pt) 2020-07-01
EP3157549B1 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
PT3157549T (pt) Nova imunoterapia contra vários tumores do sangue, em particular a leucemia linfoide crónica (llc)
ZA202005298B (en) Combination tumor immunotherapy
DK3140319T3 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
IL243788B (en) New immunotherapy against various tumors such as lung cancer which includes nsclc
EP3094342A4 (en) Anti-tumor therapy
GB201507030D0 (en) Immunotherapy against lung cancers, in particular NSCLC
IL252053A0 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
IL295031B1 (en) Innovative immunotherapy against several tumors, such as lung cancer, including nsclc
EP3098540A4 (en) Heat pump apparatus
EP3157553A4 (en) Treatment for chronic lymphocytic leukemia (cll)
EP3152579A4 (en) Molecular mammography
EP3163206A4 (en) Heat pump apparatus
EP3204001A4 (en) Avocado-derived lipids for use in treating leukemia
IL271367A (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
IL249533A0 (en) Treatment of chronic lymphocytic leukemia
GB201403297D0 (en) Novel immunotherapy against several tumors, such as lung cancer, including NSCLC
GB201313987D0 (en) Novel immunotherapy against several tumors, such as lung cancer including NSCLC
GB201519261D0 (en) Novel Immunotherapeutic treatments for tumours
TWM490263U (en) Adjustable table